Salt Lake City, UTAH1 Active Studies

Systemic Mastocytosis Clinical Trials in Salt Lake City, UTAH

Find 1 actively recruiting systemic mastocytosis clinical trials in Salt Lake City, UTAH. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
534
Enrolling

Recruiting Systemic Mastocytosis Studies in Salt Lake City

About Systemic Mastocytosis Clinical Trials in Salt Lake City

Systemic mastocytosis is a rare condition caused by accumulation of abnormal mast cells in the bone marrow, skin, liver, spleen, and GI tract. It can cause allergic reactions, bone pain, and organ damage. Treatment includes targeted therapies, antihistamines, and mast cell stabilizers.

There are currently 1 systemic mastocytosis clinical trials recruiting participants in Salt Lake City, UTAH. These studies are seeking a combined 534 participants. Research is being sponsored by Blueprint Medicines Corporation. Clinical trial participation is free and participants receive study-related medical care at no cost.

Systemic Mastocytosis Clinical Trials in Salt Lake City — FAQ

Are there systemic mastocytosis clinical trials in Salt Lake City?

Yes, there are 1 systemic mastocytosis clinical trials currently recruiting in Salt Lake City, UTAH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Salt Lake City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you about next steps.

Are clinical trials in Salt Lake City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Salt Lake City studies also compensate for your time and travel.

What systemic mastocytosis treatments are being tested?

The 1 active trials in Salt Lake City are testing new therapies including novel drugs, biologics, and treatment approaches for systemic mastocytosis.

Data updated March 2, 2026 from ClinicalTrials.gov